UNLABELLED: We sought to advance methodology for studying microglial activation and putative therapeutic downregulation in response to minocycline by means of noninvasive in vivo imaging. A reproducible focal white matter lesion was used to reliably compare treatment conditions. METHODS: The corpus callosum of female Sprague Dawley rats was injected with zymosan to promote microglial activation as confirmed by hematoxylin and eosin staining, (3)H-PK11195 autoradiography, and CD11b immunohistochemistry. A subset of subjects was treated systemically with minocycline to potentially alter microglial activation. Seven days after zymosan injection, subjects were imaged with PET using the radiotracer (11)C-(R)-PK11195. In vivo binding was evaluated using the distribution volume ratio (DVR) with respect to a reference region. RESULTS: At the lesion site, the observed (11)C-(R)-PK11195 DVR for each treatment was as follows: mean saline DVR ± SD, 1.17 ± 0.05 (n = 5); zymosan-only DVR, 1.96 ± 0.33 (n = 10); and zymosan with minocycline DVR, 1.58 ± 0.12 (n = 9). Therefore, compared with controls, zymosan increased binding (P = 0.0001, 2-tailed t test) and minocycline treatment reduced zymosan-induced binding by 46% (P = 0.004, 2-tailed t test). CONCLUSION: Zymosan-induced microglial activation and its response to minocycline can be quantitatively imaged in the rat brain using (11)C-(R)-PK11195 PET. The ability to detect a treatment effect in a focal white-matter lesion may be of use in studying therapies for multiple sclerosis (MS).
UNLABELLED: We sought to advance methodology for studying microglial activation and putative therapeutic downregulation in response to minocycline by means of noninvasive in vivo imaging. A reproducible focal white matter lesion was used to reliably compare treatment conditions. METHODS: The corpus callosum of female Sprague Dawley rats was injected with zymosan to promote microglial activation as confirmed by hematoxylin and eosin staining, (3)H-PK11195 autoradiography, and CD11b immunohistochemistry. A subset of subjects was treated systemically with minocycline to potentially alter microglial activation. Seven days after zymosan injection, subjects were imaged with PET using the radiotracer (11)C-(R)-PK11195. In vivo binding was evaluated using the distribution volume ratio (DVR) with respect to a reference region. RESULTS: At the lesion site, the observed (11)C-(R)-PK11195 DVR for each treatment was as follows: mean salineDVR ± SD, 1.17 ± 0.05 (n = 5); zymosan-only DVR, 1.96 ± 0.33 (n = 10); and zymosan with minocyclineDVR, 1.58 ± 0.12 (n = 9). Therefore, compared with controls, zymosan increased binding (P = 0.0001, 2-tailed t test) and minocycline treatment reduced zymosan-induced binding by 46% (P = 0.004, 2-tailed t test). CONCLUSION:Zymosan-induced microglial activation and its response to minocycline can be quantitatively imaged in the rat brain using (11)C-(R)-PK11195 PET. The ability to detect a treatment effect in a focal white-matter lesion may be of use in studying therapies for multiple sclerosis (MS).
Authors: Natalija Popovic; Anna Schubart; Brian D Goetz; Su-Chun Zhang; Chris Linington; Ian D Duncan Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: Daniel J Rubins; William P Melega; Goran Lacan; Baldwin Way; Alain Plenevaux; Andre Luxen; Simon R Cherry Journal: Neuroimage Date: 2003-12 Impact factor: 6.556
Authors: Luanne M Metz; Yunyan Zhang; Michael Yeung; David G Patry; Robert B Bell; Cristina A Stoian; V Wee Yong; Scott B Patten; Pierre Duquette; Jack P Antel; J Ross Mitchell Journal: Ann Neurol Date: 2004-05 Impact factor: 10.422
Authors: B C Tilley; G S Alarcón; S P Heyse; D E Trentham; R Neuner; D A Kaplan; D O Clegg; J C Leisen; L Buckley; S M Cooper; H Duncan; S R Pillemer; M Tuttleman; S E Fowler Journal: Ann Intern Med Date: 1995-01-15 Impact factor: 25.391
Authors: J C Debruyne; J Versijpt; K J Van Laere; F De Vos; J Keppens; K Strijckmans; E Achten; G Slegers; R A Dierckx; J Korf; J L De Reuck Journal: Eur J Neurol Date: 2003-05 Impact factor: 6.089
Authors: R B Banati; J Newcombe; R N Gunn; A Cagnin; F Turkheimer; F Heppner; G Price; F Wegner; G Giovannoni; D H Miller; G D Perkin; T Smith; A K Hewson; G Bydder; G W Kreutzberg; T Jones; M L Cuzner; R Myers Journal: Brain Date: 2000-11 Impact factor: 13.501
Authors: Peter S Bloomfield; Sudhakar Selvaraj; Vincenzo de Paola; Oliver D Howes; Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; David R Owen; Michael Ap Bloomfield; Ilaria Bonoldi; Nicola Kalk; Federico Turkheimer; Philip McGuire Journal: Am J Psychiatry Date: 2015-10-16 Impact factor: 18.112
Authors: Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey Journal: Neurobiol Dis Date: 2020-07-24 Impact factor: 5.996
Authors: Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis Journal: Pharmacol Biochem Behav Date: 2019-01-26 Impact factor: 3.533
Authors: Frederick M Lartey; G-One Ahn; Rehan Ali; Sahar Rosenblum; Zheng Miao; Natasha Arksey; Bin Shen; Marta Vilalta Colomer; Marjan Rafat; Hongguang Liu; Miguel A Alejandre-Alcazar; John W Chen; Theo Palmer; Frederick T Chin; Raphael Guzman; Billy W Loo; Edward Graves Journal: Mol Imaging Biol Date: 2014-12 Impact factor: 3.488
Authors: Sudhakar Selvaraj; Peter S Bloomfield; Bo Cao; Mattia Veronese; Federico Turkheimer; Oliver D Howes Journal: Schizophr Res Date: 2017-10-12 Impact factor: 4.939